Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
symbols : SCLX save search
Scilex Holding Company Announces $15 Million Registered Direct Offering
Published: 2024-04-24 (Crawled : 12:00) - globenewswire.com
SCLX | $0.85 -12.97% -16.18% 480
|
|
| O: -6.35%
H: 3.33%
C: -5.56%
company million direct offering
Scilex Holding Company Provides Certain Preliminary Unaudited Financial Results For Gross and Net Sales for ZTlido® for the First Quarter 2024; Implements Planned 2024 Commercial Ramp for Additional Opioid Sparing Product and Reduction of R&D and Other Administrative Expenses
Published: 2024-04-16 (Crawled : 13:00) - globenewswire.com
SCLX | $0.85 -12.97% -16.18% 480
|
|
| O: -1.56%
H: 0.0%
C: -7.94%
ztlido sales first company opioid for commercial financial results
Scilex Holding Company Announces Launching of Co-Pay Programs for Both ZTlido® and ELYXYB® for Commercially Insured Patients and the addition of ELYXYB® to a Multi-State Medicaid Pharmaceutical Purchasing Group to Its Purchasing Pool
Published: 2024-04-09 (Crawled : 13:00) - globenewswire.com
SCLX | $0.85 -12.97% -16.18% 480
|
|
| O: -7.28%
H: 7.86%
C: -2.86%
ztlido company group for
Scilex Holding Company Announces that the U.S. Bankruptcy Court has Extended the Lockup Period on Shares of Scilex Stock Previously Distributed by Sorrento to its Stockholders as a Dividend
Published: 2024-03-27 (Crawled : 13:00) - globenewswire.com
SCLX | $0.85 -12.97% -16.18% 480
|
|
| O: -0.66%
H: 10.33%
C: 7.33%
SRNE | $0.02 33.33% -8.85% 0
|
Health Technology
|
| O: -11.11%
H: 12.5%
C: 0.0%
company
Scilex Holding Company Announces New Out-of-Pocket Costs for Commercially Insured Patients
Published: 2024-03-21 (Crawled : 13:30) - globenewswire.com
SCLX | $0.85 -12.97% -16.18% 480
|
|
| O: 1.47%
H: 1.45%
C: 1.45%
company
Scilex Holding Company Announces Seeking Approval from the FDA for Modification of the Gloperba® Label to Provide Specific Dosing Guidance for Patients with Renal Impairment and Other Circumstances Where Dose Adjustment is Needed
Published: 2024-03-20 (Crawled : 15:00) - globenewswire.com
SCLX | $0.85 -12.97% -16.18% 480
|
|
| O: 0.0%
H: 3.7%
C: 0.74%
gloperba fda label company renal approval
Scilex Holding Company Announces a Settlement Agreement with Takeda Pharmaceuticals to Resolve the Paragraph IV Patent Infringement Lawsuit Relating to Scilex’s Filing of a sNDA with the FDA Seeking to Expand the Label for its FDA-Approved Liquid Colchicine Product, Gloperba®
Published: 2024-03-20 (Crawled : 13:00) - globenewswire.com
SCLX | $0.85 -12.97% -16.18% 480
|
|
| O: 0.0%
H: 3.7%
C: 0.74%
gloperba fda patent label company takeda resolve pharmaceuticals agreement
Scilex Holding Company Announces Repayment in Full of the Remaining Balance of Convertible Debentures and Early Payment of the Senior Secured Promissory Note, Paving the Way for Future Growth and Innovation
Published: 2024-03-19 (Crawled : 13:00) - globenewswire.com
SCLX | $0.85 -12.97% -16.18% 480
|
|
| O: -0.73%
H: 4.41%
C: -0.74%
ORMP A | $2.37 0.85% 1.05% 0
|
Health Technology
|
| O: -1.07%
H: 4.68%
C: 1.8%
company payment innovation growth
Scilex Holding Company Provides Responses to Product Composition Questions Related to its ELYXYB® Patent in Canada for a New Drug Submission Under Review by Health Canada for the Approval of ELYXYB®
Published: 2024-03-18 (Crawled : 14:00) - biospace.com/
SCLX | $0.85 -12.97% -16.18% 480
|
|
| O: -0.73%
H: 3.31%
C: 0.74%
elyxyb drug patent company health approval review canada submission
Scilex Holding Company Provides Responses to Product Composition Questions Related to its ELYXYB® Patent in Canada for a New Drug Submission Under Review by Health Canada for the Approval of ELYXYB® for Acute Treatment of Migraine With or Without Aura in Canada
Published: 2024-03-18 (Crawled : 13:00) - globenewswire.com
SCLX | $0.85 -12.97% -16.18% 480
|
|
| O: -0.73%
H: 3.31%
C: 0.74%
elyxyb drug patent company health approval review treatment canada migraine submission
Scilex Holding Announces Issuance of Halal Certification for its ZTlido® product by Circle H International, Inc.
Published: 2024-03-15 (Crawled : 19:00) - globenewswire.com
SCLX | $0.85 -12.97% -16.18% 480
|
| Email alert
Add to watchlist
ztlido certification
Scilex Holding Company’s Wholly Owned Subsidiary, Scilex Pharmaceuticals Inc., Entered into a Definitive Mutual Release and Settlement Agreement with Virpax Pharmaceuticals, Inc. Relating to the Previously Announced Term Sheet with Virpax in Respect of Such Release and Settlement
Published: 2024-03-15 (Crawled : 13:00) - globenewswire.com
SCLX | $0.85 -12.97% -16.18% 480
|
|
| O: 0.72%
H: 2.89%
C: -2.14%
SRNE | $0.02 33.33% -8.85% 0
|
Health Technology
|
| O: -7.14%
H: 46.15%
C: 38.46%
virpax wholly pharmaceuticals agreement
Scilex Holding Company Announces Closing of $10 Million Bought Deal Offering
Published: 2024-03-05 (Crawled : 21:00) - globenewswire.com
SCLX | $0.85 -12.97% -16.18% 480
|
|
| O: 0.76%
H: 12.12%
C: 3.03%
company million offering deal
Scilex Holding Company Sets Launch Price of $595 per 150ml bottle of Gloperba®, its First and Only Liquid Oral Version of the Anti-Gout Medicine Colchicine Indicated for the Prophylaxis of Painful Gout Flares in Adults; Expected Plans to Launch in the First Half of 2024
Published: 2024-03-05 (Crawled : 14:00) - globenewswire.com
SCLX | $0.85 -12.97% -16.18% 480
|
|
| O: -2.24%
H: 1.53%
C: 0.0%
gloperba first company expected
Scilex Holding Company Launches New Website to Showcase Growing Portfolio of Non-Opioid Products and Pipeline Information Updates
Published: 2024-03-04 (Crawled : 14:00) - globenewswire.com
SCLX | $0.85 -12.97% -16.18% 480
|
|
| O: 3.37%
H: 2.17%
C: -2.9%
company pipeline growing
Scilex Holding Company Announces that the Official Committee of Unsecured Creditors of Sorrento Therapeutics, Inc., has Filed a Motion with the U.S. Bankruptcy Court to Extend the Lockup Period on Shares of Scilex Stock Previously Distributed by Sorrento to its Stockholders as a Dividend from March 31, 2024 to September 30, 2024
Published: 2024-03-02 (Crawled : 00:20) - globenewswire.com
SCLX | $0.85 -12.97% -16.18% 480
|
| Email alert
Add to watchlist
SRNE | $0.02 33.33% -8.85% 0
|
Health Technology
| Email alert
Add to watchlist
company
Scilex Holding Company Announces $10 Million Bought Deal Offering
Published: 2024-02-29 (Crawled : 22:00) - globenewswire.com
SCLX | $0.85 -12.97% -16.18% 480
|
|
| O: -32.6%
H: 0.65%
C: -12.75%
company million offering deal
Scilex Holding Company Announces Major Initiative with a Leading National Pharmacy Chain to Stock GLOPERBA® in Most of Their Stores Throughout the U.S.
Published: 2024-02-28 (Crawled : 14:00) - globenewswire.com
SCLX | $0.85 -12.97% -16.18% 480
|
|
| O: 3.46%
H: 2.72%
C: 1.26%
gloperba pharmacy company initiative
Scilex Holding Company Announces Acceptance of Abstract for Poster and Oral Presentation at the Annual Meeting of the American Academy of Pain Medicine (AAPM)
Published: 2024-02-27 (Crawled : 14:00) - globenewswire.com
SCLX | $0.85 -12.97% -16.18% 480
|
|
| O: 1.45%
H: 15.24%
C: 10.0%
company presentation meeting
Scilex Holding Company’s Wholly Owned Subsidiary, Scilex Pharmaceuticals Inc., Enters into a Term Sheet with Virpax Pharmaceuticals, Inc. Regarding a Mutual Release and Settlement Agreement
Published: 2024-02-26 (Crawled : 22:00) - globenewswire.com
SCLX | $0.85 -12.97% -16.18% 480
|
|
| O: 1.45%
H: 15.24%
C: 10.0%
SRNE | $0.02 33.33% -8.85% 0
|
Health Technology
|
| O: 7.14%
H: 66.67%
C: -11.0%
virpax wholly pharmaceuticals agreement
Gainers vs Losers
| 50% | 50% |
Top 10 Gainers
CSSE 4 | $0.299 96.32% 7M
|
Consumer Services
BRFH 4 | $1.99 80.91% 13M
|
Manufacturing
BOF | $1.915 63.68% 620K
|
AMST | $3.13 56.5% 500K
|
Technology Services
ACON | $0.3595 24.83% 3.5M
|
n/a
CDTX | News | $14.57 18.55% 330K
|
Health Technology
ULBI M | $10.12 15.92% 120K
|
Producer Manufacturing
LRHC | $1.79 11.88% 3K
|
n/a
AIXI | $1.34 8.94% 42K
|
n/a
TRU | $74.475 8.44% 100K
|
Technology Services
Your saved searches
Save your searches and get alerts when important news are released.